| Literature DB >> 33374332 |
Kathryn Hughes Barry1,2, Kareshma Mohanty1, Patricia A Erickson1, Difei Wang3, Jianxin Shi3, Gary Rose4, Ashley Cellini5, Kimberly Clark5, Nicholas Ambulos2,6, Jing Yin2,6, Liying Yan7, Matthew Poulin7, Ann Meyer7, Yuji Zhang1,2, Søren M Bentzen1,2, Allen Burke4, Arif Hussain2,8,9, Sonja I Berndt10.
Abstract
Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether MYC DNA methylation at 8q24 (six CpG sites from exon 3 to the 3' UTR) in prostate tumor was associated with tumor aggressiveness (based on Gleason score, GS), and we incorporated RNA expression data to investigate the function. We accessed radical prostatectomy tissue for 50 Caucasian and 50 African American prostate cancer patients at the University of Maryland Medical Center, selecting an equal number of GS 6 and GS 7 cases per group. MYC DNA methylation was lower in tumor than paired normal prostate tissue for all six CpG sites (median difference: -14.74 to -0.20 percentage points), and we observed similar results for two nearby sites in The Cancer Genome Atlas (p < 0.0001). We observed significantly lower methylation for more aggressive (GS 7) than less aggressive (GS 6) tumors for three exon 3 sites (for CpG 212 (chr8:128753145), GS 6 median = 89.7%; GS 7 median = 85.8%; p-value = 9.4 × 10-4). MYC DNA methylation was not associated with MYC expression, but was inversely associated with PRNCR1 expression after multiple comparison adjustment (q-value = 0.04). Findings suggest that prostate tumor MYC exon 3 hypomethylation is associated with increased aggressiveness.Entities:
Keywords: DNA methylation; Gleason score (GS); MYC; RNA expression; aggressive disease; non-coding RNAs (ncRNAs); prostate cancer; tumor tissue biomarkers
Mesh:
Substances:
Year: 2020 PMID: 33374332 PMCID: PMC7823928 DOI: 10.3390/genes12010012
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096